… EGFR mutations with clinical factors predictive of response to erlotinib or gefitinib, we found
that … with patients with EGFR L858R after treatment with erlotinib or gefitinib (P = 0.01). …

… of adjuvant erlotinib or gefitinib delivery were recorded. Patients at MSKCC receive adjuvant
erlotinib or gefitinib by enrolling in phase 2 clinical trials, 24 , 25 or outside of a clinical trial. …

… and acquired clinical resistance to gefitinib and/or erlotinib … clinical trials, we evaluated the
disease course and associated clinical and molecular factors of patients enrolled on clinical …

… We developed a clinical significance curve and risk-benefit contour to illustrate how the …
-Lung 7 to estimate the additional clinical benefit of afatinib versus gefitinib 5 and the results of …

… gefitinib or erlotinib significantly lowers the risk of CNS progression during the disease course
… Therefore, we retrieved information on the clinical presentation and course of our patients …

… kinase inhibitors, gefitinib and erlotinib, on … clinical presentation and course of our patients
with advanced NSCLC and somatic EGFR mutations initially treated with gefitinib or erlotinib …

… progression of disease after discontinuation of erlotinib or gefitinib in patients … resistance to
erlotinib or gefitinib, continued treatment with erlotinib or … Clinical course of individual patients …

… clinical course of 18 EGFR mutated NSCLC that were treated with gefitinib and, on resistance,
erlotinib… exon 19 deletions), and initial response to gefitinib 250 mg/d were consistent with …

… the clinical course of patients with the longest three PFS (13.8, 12.4, and 11.6 months), gefitinib
was directly switched to erlotinib … In the clinical course of treatment with EGFR-TKIs, CNS …

… The best overall tumor responses (complete response (CR), partial response (CR), stable
disease (SD), progressive disease (PD)) during the course of different treatment modalities …